The increase in glucagon-like peptide-1 (GLP-1) activity has emerged as a useful therapeutic tool of achieving and maintaining good gylcemic control with concomitant weight loss in T2D with obesity[5,6,8]. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.